Updated international consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan(Queen Mary University of London), Donald M. Arnold(Canadian Blood Services), James B. Bussel(Cornell University), Beng H. Chong(UNSW Sydney), Nichola Cooper(Hammersmith Hospital), Terry Gernsheimer(Seattle Cancer Care Alliance), Waleed Ghanima(University of Oslo), Bertrand Godeau(Université Paris-Est Créteil), Tomás José González‐López(Hospital Universitario de Burgos), John D. Grainger(Royal Manchester Children's Hospital), Ming Hou(Qilu Hospital of Shandong University), Caroline Kruse, Vickie McDonald(Barts Health NHS Trust), Marc Michel(Université Paris-Est Créteil), Adrian C. Newland(Queen Mary University of London), Sue Pavord(University of Oxford), Francesco Rodeghiero(Ospedale San Bortolo), Marie Scully(University College Hospital), Yoshiaki Tomiyama(Osaka University Hospital), Raymond Wong(Chinese University of Hong Kong), Francesco Zaja(Azienda Sanitaria Universitaria Integrata di Trieste), David J. Kuter(Harvard University)
Cited by 1,070Open Access
Abstract
Abstract Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This article is an update of the International Consensus Report published in 2010. A critical review was performed to identify all relevant articles published between 2009 and 2018. An expert panel screened, reviewed, and graded the studies and formulated the updated consensus recommendations based on the new data. The final document provides consensus recommendations on the diagnosis and management of ITP in adults, during pregnancy, and in children, as well as quality-of-life considerations.
Related Papers
No related papers found
Powered by citation graph analysis